GLGonzalo Lázaro

Gonzalo Lázaro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gonzalo Lázaro has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Andrea Aran

    Immunology Unit, Department of Cell Biology, Physiology and Immunology Institut de Biotecnologia i Biomedicina (IBB), Universitat Autònoma de Barcelona (UAB) Bellaterra Spain

    1 shared publication
  • Carme Roura‐Mir

    Immunology Unit, Department of Cell Biology, Physiology and Immunology Institut de Biotecnologia i Biomedicina (IBB), Universitat Autònoma de Barcelona (UAB) Bellaterra Spain

    1 shared publication
  • Javier Cortés

    International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group Barcelona Spain

    1 shared publication
  • Javier Román‐García

    Medical Oncology Department IOB Institute of Oncology‐Madrid Madrid Spain

    1 shared publication
  • José Pérez‐García

    International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group Barcelona Spain

    1 shared publication
  • Juan A. Cedano

    Department of Biochemistry and Molecular Biology Institut de Biotecnologia i Biomedicina (IBB), Universitat Autònoma de Barcelona (UAB) Bellaterra Spain

    1 shared publication

Latest Publications

  • Open Access

    HLA ‐ DRB1 Allelic Combinations Differentially Shape Dendritic Cell Antigen Presentation Enhanced by Tumour Cell Line Lysate‐Pulsing

    by Gonzalo Lázaro, Juan A. Cedano, Maitane Faus, Carme Roura‐Mir, Laia Garrigós, José Pérez‐García, Javier Román‐García, Javier Cortés, Andrea Aran, Mercè Martí

    The anti‐tumour immune response plays a pivotal role in eliminating tumour cells, with the presence of tumour‐infiltrating lymphocytes (TILs) often correlated with improved patient outcomes. Among these, CD4+ T lymphocytes act as key orchestrators of the immune response, functioning as effector and regulatory cells, and are essential for establishing immunological memory. To better understand the role of CD4+ T cells in anti‐tumour immunity, we analysed the HLA‐II immunopeptidome of dendritic cells (DCs) from HLA‐heterozygous donors pulsed with a protein extract from the MCF‐7 tumour cell line. Our objective was to identify differences in the arrays of peptides binding distinct HLA‐DRB1 allele combinations and the effect of DC pulsing on peptide presentation. We found that presented peptide repertoires are strongly influenced by HLA‐DR heterozygosity in an allele‐specific manner. Alleles with high binding strength (e.g., DRB1*01:01 , DRB1*03:01 and DRB1*04:04 ) tended to dominate peptide presentation; however, this dominance is significantly modulated by the allelic combination, suggesting that antigen presentation is shaped not only by individual allele properties but also by their combinations. Pulsing DCs with MCF‐7 extracts increased peptide overlap between donors and enabled the identification of 58 proteins putatively derived from the tumour cell line lysates. Interestingly, peptide presentation from these proteins reinforced allele‐specific features of dominance and weakness previously observed across the entire immunopeptidome. Gaining insights into the peptide repertoire presented by distinct HLA‐DR combinations could inform the design of personalised immunotherapies based on peptide‐pulsed DCs, ultimately enhancing CD4+ TIL responses across diverse patient populations.